On September 25, Molecular Designs announced that it entered into an agreement to acquire Lamda Biotech.
Lamda Biotech is a specialized provider of research products for application in molecular biology, functional genomics, proteomics and gene therapy. For more than 20 years, Lamda Biotech has been highly regarded for its offering of cutting-edge PCR products, RT-PCR reagents, RT-qPCR kits, Direct-PCR genotyping kits, DNA ladders, SafeStain and other protein and cell biology products.
Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. It offers numerous multiplex PCR-based panels produced under GMP and ISO 13485:2016 quality standards for research use, as well as complementary reagents and instrumentation.
The acquisition of Lamda Biotech solidifies Molecular Designs’ position as a key player in the molecular technology market and demonstrates a commitment to providing customers with the highest quality lab products and research solutions. Terms were not disclosed.
Michael Clark, CEO of Molecular Designs, notes, “This acquisition is a significant milestone for Molecular Designs. It brings together best in class manufacturing and specialized product expertise that has the power to better support our clients.”
According to data captured in the LevinPro HC database, this acquisition represents the 108th Biotechnology transaction of 2024. Between January 1, 2023, and September 25, 2023, there were 115 Biotechnology acquisitions reported.
